Biological role of metabolic reprogramming of cancer cells during epithelial‑mesenchymal transition (Review)

Oncol Rep. 2019 Feb;41(2):727-741. doi: 10.3892/or.2018.6882. Epub 2018 Nov 23.

Abstract

Epithelial‑mesenchymal transition (EMT) is required for the distant metastasis of tumors. The degree of tumor malignancy increases as EMT progresses. Notably, the biology of tumor cells differs from that of normal cells, with regards to characteristics and energy metabolism mechanisms; abnormal glucose metabolism, excessive accumulation of fatty acids and other metabolic disorders occur in metastatic tumors. Previous studies have confirmed that the regulation of tumor cell metabolism can affect tumor metastasis and some findings have resulted in novel clinical applications. The present review aimed to provide a basis for treatments targeting the tumor EMT process and metabolic reprogramming.

Publication types

  • Review

MeSH terms

  • Amino Acids / metabolism
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / metabolism*
  • Disease Progression
  • Energy Metabolism / drug effects
  • Epithelial-Mesenchymal Transition / drug effects*
  • Glucose / metabolism
  • Glycolysis / drug effects
  • Humans
  • Lipid Metabolism / drug effects
  • Metabolic Networks and Pathways / drug effects*
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Neoplastic Stem Cells / pathology
  • Nucleic Acids / metabolism

Substances

  • Amino Acids
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Nucleic Acids
  • Glucose